Diaceutics PLC
LSE:DXRX

Watchlist Manager
Diaceutics PLC Logo
Diaceutics PLC
LSE:DXRX
Watchlist
Price: 116 GBX
Market Cap: 97.9m GBX
Have any thoughts about
Diaceutics PLC?
Write Note

Diaceutics PLC
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Diaceutics PLC
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Diaceutics PLC
LSE:DXRX
Income from Continuing Operations
-ÂŁ1.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Oxford Nanopore Technologies PLC
LSE:ONT
Income from Continuing Operations
-ÂŁ154.5m
CAGR 3-Years
-36%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Income from Continuing Operations
-ÂŁ5m
CAGR 3-Years
31%
CAGR 5-Years
10%
CAGR 10-Years
-13%
Ergomed PLC
LSE:ERGO
Income from Continuing Operations
ÂŁ15m
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Income from Continuing Operations
ÂŁ10.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Income from Continuing Operations
ÂŁ17.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Diaceutics PLC
Glance View

Market Cap
98.3m GBX
Industry
Life Sciences Tools & Services

Diaceutics Plc engages in the provision of data, data analytics and implementation services. The company is headquartered in Belfast, Northern Ireland. The company went IPO on 2019-03-21. The principal activity of the Company is data analytics and implementation services. The firm is engaged in research and development activities in drug development science, testing data and software platform development. The firm's implementation services include test standardization, test quality assessment, laboratory tech support and others. The firm has established a range of products and outsourced advisory services, which help its pharma clients to optimize and deliver their marketing and implementation strategies for companion diagnostics. The firm provides the pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network. DXRX is the diagnostic commercialization platform for precision medicine, integrating multiple pipelines of diagnostic testing data from a global network of laboratories.

DXRX Intrinsic Value
155.87 GBX
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Diaceutics PLC's Income from Continuing Operations?
Income from Continuing Operations
-1.7m GBP

Based on the financial report for Dec 31, 2023, Diaceutics PLC's Income from Continuing Operations amounts to -1.7m GBP.

Back to Top